Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical company has received approval from United States Food and Drug Administration (USFDA) for marketing approval for OraVerse (phentolamine mesylate).
OraVerse is the pharmaceutical agent indicated for the reversal of softtissue anaesthesia and the associated functional deficits resulting from a local dental aesthetic. Novalar is establishing a specialty direct sales force to launch OraVerse in late 2008.
Novalar plans to launch OraVerse at this year's American Dental Association (ADA) Annual Session being held in San Antonio, Texas from October 16-20, 2008. Novalar's sales force will focus on general and paediatric dentists for use in patients over six years of age.